Change of 8.77% for THROMBOGENICS NV ORDINARY SHARES BELGIU (OTCMKTS:TBGNF)’s shorted shares was registered. It was announced in November by FINRA the 55,100 shorted shares on TBGNF. The 60,400 previous shares are down with 8.77%. 551 days will cost TBGNF with 100 average volume to restore its former position.
$5.55 was the last price.Since November 10, 2017 it’s 0.00% down thus . TBGNF underperformed by 15.62% the S&P 500.
ThromboGenics NV, an integrated biopharmaceutical company, develops and commercializes medicines that address unmet clinical needs in ophthalmology in Belgium and internationally.The firm is worth $239.99 million. The company's lead product is JETREA used for the treatment of symptomatic vitreomacular adhesion and vitreomacular traction.7.86 is the P/E ratio. It has research and development agreements with BioInvent International AB to develop Anti-PlGF, a product candidate to treat Medulloblastoma, a pediatric malignant brain tumor; Eleven Biotherapeutics and Bicycle Therapeutics to develop and commercialize products for the treatment of eye diseases with diabetics; and Chilltern International, Inc. and Outcome Sciences, Inc., as well as Parexel to provide clinical research services for the development of JETREA.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.